| XU, Zhi |
NCT05641207: A Clinical Evaluation of the RheOx Bronchial Rheoplasty System |
|
|
| Recruiting | N/A | 40 | RoW | RheOx™ with the RheOx™ Catheter treated in the trial | Energenx Medical LTD. | Chronic Bronchitis, Chronic Obstructive Pulmonary Disease | 08/25 | 08/25 | | |
| Zhang, Xi |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Relapsed or Refractory Acute Lymphoblastic Leukemia | 09/22 | 12/26 | | |
NCT04716686: Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma |
|
|
| Recruiting | 2 | 83 | RoW | Niraparib | Shandong University, Sun Yat-sen University, Tongji Hospital, Women's Hospital School Of Medicine Zhejiang University, Zai Lab (Shanghai) Co., Ltd. | Endometrial Carcinoma, Serous Carcinoma | 12/25 | 12/26 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL |
|
|
| Recruiting | 1/2 | 84 | RoW | ATG-010, Selinexor, Lenalidomide, Rituximab | Antengene Corporation | Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | 03/25 | 06/25 | | |
NCT04637269: Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma |
|
|
| Recruiting | 1 | 16 | RoW | anti-BCMA CAR-T | Xinqiao Hospital of Chongqing, Carbiogene Therapeutics Co. Ltd. | Multiple Myeloma | 11/21 | 11/23 | | |
NCT04639739: Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. |
|
|
| Not yet recruiting | 1 | 9 | RoW | anti-CD19 CAR NK | Xinqiao Hospital of Chongqing, Chongqing Precision Biotech Co., Ltd | NHL | 12/21 | 12/23 | | |
NCT04264078: Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | CD7 UCAR-T cells, Fludarabine, Cytoxan, Melphalan | Xinqiao Hospital of Chongqing, Gracell Biotechnology Shanghai Co., Ltd., 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, Central South University, The First Affiliated Hospital of Kunming Medical College, The General Hospital of Western Theater Command, Second Affiliated Hospital of Xi'an Jiaotong University, Nanfang Hospital of Southern Medical University, Fujian Medical University Union Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital | T-cell Leukemia, T-cell Lymphoma | 06/22 | 06/23 | | |
| Zhu, Bo |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
NCT04139057: EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC |
|
|
| Recruiting | 1/2 | 18 | RoW | EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Xinqiao Hospital of Chongqing, TCRCure Biopharma Ltd. | Head and Neck Squamous Cell Carcinoma | 12/24 | 12/24 | | |
NCT06239298: A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 130 | RoW | ZG005 Powder for Injection, ZG005, Donafenib Tosilate Tablets, Donafenib | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumor | 03/26 | 05/26 | | |
| Recruiting | 1/2 | 115 | RoW | SHR-3276 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/27 | 12/28 | | |
| Terminated | N/A | 13 | RoW | | GeneCast Biotechnology Co., Ltd., Xinqiao Hospital of Chongqing, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Wuhan University, Renmin Hospital of Wuhan University, Tongji Hospital, Southwest Hospital, China, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, People's Hospital of Chongqing, Sichuan Cancer Hospital and Research Institute, The Second Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Wenzhou Medical University, The Affiliated Hospital Of Southwest Medical University, Guizhou Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Shanxi Provincial Cancer Hospital, First Hospital of China Medical University, Fujian Provincial Hospital, Peking University Shenzhen Hospital, Affiliated Cancer Hospital of Shantou University Medical College, The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Non-small Cell Lung Cancer, Neoantigen, Next-generation Sequencing, Biomarker | 12/21 | 12/21 | | |
| Lv, Shengqing |
NCT04918420: A Single-arm Trial of the Flow Diverter (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 142 | RoW | Flow Diverter (Tonbridge) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Aneurysm | 03/23 | 03/27 | | |
